Speaker illustration

Doctor Corina Becker

Bayer AG, Wuppertal (Germany)

Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Cardiovascular Pharmacotherapy

Session: Pharmacology and Pharmacotherapy ePosters

Thumbnail

Pharmacodynamic interaction study of a long-acting nitrate co-administered with vericiguat in patients with stable coronary artery disease

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Cardiovascular Pharmacotherapy, Other

Session: Pharmacology and Pharmacotherapy

Thumbnail

Pharmacodynamic and pharmacokinetic interaction profile of vericiguat

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Cardiovascular Pharmacotherapy, Other

Session: Pharmacology and Pharmacotherapy

Thumbnail

Safety, pharmacodynamic and pharmacokinetic characterisation of vericiguat: key results from six phase I studies in healthy subjects

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Cardiovascular Pharmacotherapy, Other

Session: Pharmacology and Pharmacotherapy

Thumbnail

This platform is supported by

logo Novo Nordisk